GSK reached a settlement with a man who claimed the drugmaker’s blockbuster heartburn medication Zantac caused his cancer, heading off the first such case set to go to trial in the US.

The parties reached a confidential settlement and the case filed in a California state court will be dismissed, the British pharmaceutical giant said in a statement Friday. The company said it isn’t admitting any liability in the settlement and will continue to defend itself in all other cases related to the drug. Shares of GSK rose as much as 4.8%.

“This is a positive for GSK shares as it removes any negative headline risk from a potential judgment from a jury this year,” wrote Emily Field, an analyst at Barclays.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

BenefitsPRO Broker Expo 2024Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.